Adrenocortical
carcinoma, also known as adrenal cortex carcinoma, is a rare form of
cancer that occurs at the cortex layer of the adrenal gland. There are two
adrenal glands present in the human body: one at the top of each kidney. Each
adrenal gland is comprised of two distinct structures: the outer part of the adrenal
glands (adrenal cortex) and the inner region (adrenal medulla).
Some of the genetic condition that can cause adrenocortical
carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann
syndrome. Some of the most common symptoms of this medical condition includes
abdominal pain, lump in the abdomen, and feeling of fullness.
Request to Get the Sample Pages at:
The disease can
be diagnosed by imaging technique such as computed tomography (CT) scan,
magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo
Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA
C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma.
Merck & Co., Inc. is also in the process of developing pembrolizumab as a
CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of
the other companies and universities having the pipeline drug for
adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc.,
HRA Pharma, and others.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
